News

P10 to Announce Q1 2025 Results with Conference Call Notice

P10 to Announce Q1 2025 Results with Conference Call Notice

P10 to Release First Quarter 2025 Earnings

DALLAS, April 17, 2025, P10, Inc. (NYSE: PX), a prominent player in providing private market solutions, has officially scheduled its earnings report for the first quarter of 2025. The announcement will be made on May 8, 2025, prior to the opening of U.S. markets.

Conference Call and Webcast Details

On the same day as the earnings release, the company will host an important conference call and live webcast at 8:30 a.m. Eastern Time. This event will allow shareholders and potential investors to gain insights into the company’s performance and future outlook directly from company executives.

Accessing the Webcast

To join the webcast, participants can connect through the official channels on P10's investor relations page. It's an excellent opportunity to stay informed about the company's strategic developments and financial health.

Participating via Telephone

For those who prefer to join by phone, registration is required to obtain dial-in and PIN numbers, ensuring direct access to the event. This telephone participation allows for a more personal connection to company representatives.

Post-Call Availability

If you’re unable to attend the live session, P10 will provide a replay available on its investor relations page. This accessibility ensures that all stakeholders can remain engaged with the company’s developments even if they miss the live event.

About P10

P10 is a trailblazer in the world of alternative asset management. As a multi-asset class private markets solutions provider, its mission centers around delivering unique investment opportunities tailored to meet the varied needs of its investors. With a thriving global investor community exceeding 3,800 across numerous geographical locations—including over 60 countries—P10 has refined its offerings to appeal to diverse institutional clients, including large pension funds, endowments, foundations, and major financial institutions.

Commitment to Investor Relations

P10's investor relations strategy is geared towards transparency and engagement. By providing in-depth insights into its investment approach and performance, the company emphasizes its commitment to maintaining robust communication with its stakeholders.

Why Attend the Earnings Release?

Attending the earnings release provides investors with valuable insights directly from the source. It allows participants to ask questions and gain clarity on financial performance, growth strategies, and future expectations.

P10 Investor Contact Information

For more details or questions, interested parties can contact P10 directly at their investor relations email. This line of communication further demonstrates the company’s intention to maintain an open dialogue with its investor base.

Connecting with P10

P10 encourages all potential investors and interested parties to explore its offerings by visiting its official website. This resource provides comprehensive information about the company, including investment options and recent developments.

Frequently Asked Questions

When will P10 release its Q1 2025 earnings?

P10 plans to release its Q1 2025 earnings on May 8, 2025, before U.S. markets open.

What time is the conference call for investors?

The conference call will commence at 8:30 a.m. Eastern Time on May 8, 2025.

How can I access the earnings conference call?

Participants can access the earnings call through a live webcast or by telephone after registering for the dial-in details.

Is there a replay available if I miss the live event?

Yes, P10 will provide a replay of the earnings call on its investor relations page for those unable to attend live.

Where can I find more information about P10?

More information about P10 can be found on their official website, which includes details on their investment offerings and company news.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 24

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading

Top 5 Most Recently Viewed Articles

Embla Medical hf Reports Strong Q2 2025 Financial Performance

Updated Category News Views 203

Embla Medical hf's Interim Report for Q2 2025 Announcement No. 33/2025 Interim Report Q2 2025 Embla Medical hf has recently published its interim report for the second quarter of 2025, revealing encouraging financial results. The organization remains committed to enhancing mobility solutions through innovative offerings in prosthetics and orthotics. Strong Sales Growth...

Continue Reading
Fly-E Group Faces Important Class Action Deadline for Investors

Updated Category News Views 185

Fly-E Group Update: Important Class Action Deadline Attention investors of Fly-E Group, Inc. If you purchased securities between July 15 and August 14, 2025, this is vital news for you. As we approach a crucial lead plaintiff deadline on November 10, 2025, the time to act is now. Understanding the Class Action The upcoming class action lawsuit revolves around Fly-E's...

Continue Reading
Royal Unibrew Posts Impressive Earnings Growth in Q3 2024

Updated Category News Views 173

Royal Unibrew's Remarkable Performance in Q3 2024 Royal Unibrew has demonstrated exceptional growth during the third quarter of 2024. The key highlights from this trading statement reveal a robust progression in organic volume and net revenue, paving the way for a bright future for the company. Strong Growth Metrics Organic Volume and Revenue Increases During Q3 2024,...

Continue Reading
Examining Medtronic PLC's Short Selling Trends and Insights

Updated Category News Views 184

Understanding Medtronic PLC's Short Interest Medtronic PLC (NYSE: MDT) has recently experienced a significant rise in its short interest as a percentage of float, currently at 17.56%. This increase signals a growing concern among investors, as the total number of shares sold short has reached 19.72 million, accounting for 1.54% of all available shares for trading. With...

Continue Reading
Palatin Technologies Announces Breakthrough in Obesity Management

Updated Category News Views 138

Positive Developments in Appetite Suppression Research Palatin Technologies, Inc. (NYSE American: PTN), a leading biopharmaceutical firm known for pioneering medications based on the melanocortin receptor system, has recently reported encouraging results concerning appetite suppression from its Phase 2 obesity study involving bremelanotide and tirzepatide. This...

Continue Reading